RT Journal Article
SR Electronic
T1 Self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women: Final analysis of efficacy and safety of a randomised controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.28.23286426
DO 10.1101/2023.02.28.23286426
A1 Laurie, Cassandra
A1 El-Zein, Mariam
A1 Botting-Provost, Sarah
A1 Tota, Joseph E.
A1 Tellier, Pierre-Paul
A1 Coutlée, François
A1 Burchell, Ann N.
A1 Franco, Eduardo L.
YR 2023
UL http://medrxiv.org/content/early/2023/03/01/2023.02.28.23286426.abstract
AB Introduction The Carrageenan-gel Against Transmission of Cervical Human papillomavirus trial’s interim analysis (June 2017, n=277) demonstrated a 36% protective effect of carrageenan against incident human papillomavirus (HPV) infections. We report the trial’s final results on efficacy and safety of a carrageenan-based gel in reducing HPV incidence and prevalence.Methods A phase IIB randomised, placebo-controlled trial, recruited healthy young women aged ≥18 primarily from health service clinics at two Canadian Universities in Montreal, Canada. Participants were randomised (1:1) to a carrageenan-based or placebo gel to be self-applied every other day for the first month and before/after intercourse. Primary outcomes were HPV type-specific incidence and clearance of prevalent infections. At each visit (months 0, 0.5, 1, 3, 6, 9, 12), participants provided questionnaire data and a self-collected vaginal sample (tested for 36 HPV types, Linear Array). Intention-to-treat analyses were conducted using Cox proportional hazards regression models. Incidence and clearance analyses were restricted to participants with ≥2 visits. Trial registration:ISRCTN96104919.Findings 461 participants (enrolled January 16th/2013–September 30th/2020) were randomised to carrageenan (n=227) or placebo (n=234) arm. Incidence, clearance, and safety analyses included 429, 240, and 461 participants, respectively. We found 51·9% (108/208) of participants in carrageenan and 66·5% (147/221) in placebo arm acquired ≥1 HPV type (hazard ratio [HR] 0·63 [95% CI: 0·49–0·81]). Among participants who tested HPV-positive at baseline, clearance (two consecutive HPV-negative visits following ≥1 positive visit) was comparable between groups; 31·8% (34/107) in carrageenan and 29·3% (39/133) in placebo arm cleared their infections (HR 1·16 [95% CI: 0·73-1·84]). Adverse events were reported by 34·8% (79/227) and 39·7% (93/234) of participants in carrageenan and placebo arm (p<0.27), respectively.Interpretation Consistent with the interim analysis, use of a carrageenan-based gel resulted in a 37% reduction in the risk of incident genital HPV infections in women. A carrageenan-based gel may complement HPV vaccination.Funding Canadian Institute of Health Research (grants MOP-106610 and FDN-143347 to ELF), CarraShield Labs Inc. (St Petersburg, FL) [provided gels in kind].Evidence before this study We published in 2021 a narrative review summarizing carrageenan’s preventive effect on human papillomavirus (HPV) based on results from 19 experimental research articles that reported on carrageenan’s anti-HPV activity. Since publication and without applying language or date restriction, we identified four additional records based on a PubMed search using the keywords “carrageenan” and “human papillomavirus” or “HPV” up to January 9th, 2023.Altogether, these records consist of ten in vitro (including 4 ex vivo), five in vitro and in vivo, three in vivo, and five clinical studies (including one post-hoc phase III randomised controlled trial [RCT], one observational study, one interim analysis of a phase IIB RCT in women, and two records for the interim analyses of a phase IIB RCT in men). Studies assessed carrageenan alone or in combination with other anti-microbial agents. The results from pre-clinical studies were consistent with a protective effect of carrageenan against HPV.Overall, eight studies were conducted in humans. The samples collected were either 1) cervicovaginal lavage samples to assess anti-HPV activity in vitro (in three ex vivo studies, two being phase I RCTs), or 2) genital samples from women (post-hoc RCT [cervical], observational study [sample type not reported], and RCT phase II [vaginal]) or anal samples from men (one study of incidence and one of clearance). In the three ex vivo studies, intravaginal use of carrageenan-containing gels was associated with strong anti-HPV activity. In a post-hoc sub study of the trial, a lower HPV prevalence in the carrageenan compared to placebo arm was found at the trial end, but only among the most compliant users (adjusted odds ratio [aOR] 0·62 [95% CI 0·41–0·94], n=348). There were, however, no baseline or intermediate measurements to assess HPV status. An observational study reported that a carrageenan-based gel may accelerate clearance of existing HPV infection (aOR 4·9 [95% CI 1·60–15·1], n=75). The interim analysis of the CATCH study found a 36% protective effect of carrageenan against incident HPV infection(s) (HR 0·64 [95% CI 0·45-0·89], n=277). Conversely, a clinical trial conducted in men who have sex with men did not demonstrate a protective effect of carrageenan on incidence (HR 1·21 [95% CI 0·86–1·70]), or clearance (HR 0·84 [95% CI 0·31–2·27]) of anal HPV infections, and reported more adverse events in the carrageenan (59·8%) relative to the placebo (39·8%) arm.Added value of this study The CATCH study is the first clinical trial designed to assess the efficacy of a carrageenan-based gel in reducing the risk of incident and prevalent HPV infections in women. Results were consistent when considering HPV subgenera and type-specific analyses. The addition of carrageenan to a lubricant gel does not appear to impact gel tolerability.Implications of all the available evidence The results of the CATCH trial indicate that carrageenan-based gels could complement HPV vaccination in protecting against HPV-related diseases. Our findings of the clinical efficacy of carrageenan may encourage future research in this area. It would be important to further examine adherence by looking at determinants of adherence, explore the possibility of the addition of carrageenan to condoms, assess the impact of a carrageenan-based gel on anal HPV infections in women, and continue research in the area of multi-purpose prevention technology for agents against HPV, HIV, and other sexually transmitted infections.Competing Interest StatementELF reports grants and personal fees from Merck, grants, personal fees and non-financial support from Roche, and personal fees from GSK, outside the submitted work. ELF and MZ hold a patent related to the discovery "DNA methylation markers for early detection of cervical cancer", registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada (October 2018). FC reports grants from Réseau FRQS-SIDA during the conduct of the study and grants to his institution for HPV-related work from Merck Sharp and Dome, Roche Diagnostics and Becton Dickinson, outside of the submitted work. JET is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, NJ, USA. P-PT, ANB, SBP, and CL have nothing relevant to this article to declare.Clinical TrialISRCTN96104919Funding StatementThe study was funded by the Canadian Institutes of Health Research (grant number MOP-106610 and grant FDN-143347 to ELF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Office (IRB) of the Faculty of Medicine and Health Sciences of McGill University, the Research Ethics Committee (CER) of the Centre Hospitalier de l'Université de Montréal, the University Human Research Ethics Committee of Concordia University, and the Research Ethics Committee (CER) of the Centre intégré de santé et de services sociaux de la Montérégie-Centre-Territoire Champlain-Charles-Le Moyne gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study will be made available online at the time of submission for publication and can be found in the McGill Dataverse at https://doi.org/10.5683/SP3/0DS6FP